INTELLIGENT BIO SOLUTIONS INC
For the period ended Jun 30, 2024. Filed Sep 18, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 18, 2024
INBS$2.25-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (LOSS)
| Year ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $3,111,781 | $1,256,872 |
| Cost of revenue (exclusive of amortization shown separately below) | (1,686,155) | (930,204) |
| Gross profit | 1,425,626 | 326,668 |
| Other income: | ||
| Government support income | 424,776 | 737,628 |
| Operating expenses: | ||
| Selling, general and administrative expenses | (9,258,496) | (8,026,703) |
| Development and regulatory approval expenses | (1,673,806) | (507,424) |
| Depreciation and amortization | (1,201,274) | (966,732) |
| Goodwill impairment | - | (4,158,670) |
| Total operating expenses | (12,133,576) | (13,659,529) |
| Loss from operations | (10,283,174) | (12,595,233) |
| Other income (expense), net: | ||
| Interest expense | (167,140) | (223,534) |
| Realized foreign exchange loss | (1,178) | (9,829) |
| Fair value gain on revaluation of financial instrument | 175,738 | 2,154,365 |
| Interest income | 84,822 | 9,676 |
| Total other income, net | 92,242 | 1,930,678 |
| Net loss | (10,190,932) | (10,664,555) |
| Net loss attributable to non-controlling interest | (34,173) | (32,835) |
| Net loss attributable to Intelligent Bio Solutions Inc. | $(10,156,759) | $(10,631,720) |
| Other comprehensive income (loss), net of tax: | ||
| Foreign currency translation gain/ (loss) | (137,118) | 212,639 |
| Total other comprehensive income (loss) | (137,118) | 212,639 |
| Comprehensive loss | (10,328,050) | (10,451,916) |
| Comprehensive loss attributable to non-controlling interest | (34,173) | (32,835) |
| Comprehensive loss attributable to Intelligent Bio Solutions Inc. | (10,293,877) | (10,419,081) |
| Net loss per share, basic and diluted* | $(6.38) | $(127.00) |
| Weighted average units outstanding, basic and diluted * | 1,592,746 | 83,717 |
| * | Common Stock and per share amounts have been retroactively adjusted to reflect the decreased number of shares resulting from the 1-for-12 Reverse Stock Split on January 26, 2024, throughout the consolidated financial statement unless otherwise stated. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.